CG Oncology (NASDAQ:CGON) Price Target Raised to $117.00

CG Oncology (NASDAQ:CGON – Free Report) had its price target boosted by Morgan Stanley from $102.00 to $117.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research analysts have also commented on the stock. Wall Street Zen raised shares of CG Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th. Wedbush lifted their target price on CG Oncology from $84.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday. HC Wainwright boosted their price target on CG Oncology from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday. Guggenheim reduced their price objective on CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Monday, November 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and an average target price of $102.22.

Read Our Latest Report on CG Oncology

CG Oncology Trading Down 3.0%

Shares of CGON stock opened at $79.47 on Wednesday. CG Oncology has a 1 year low of $37.01 and a 1 year high of $93.95. The firm’s fifty day simple moving average is $68.85 and its 200 day simple moving average is $67.24. The firm has a market capitalization of $7.10 billion, a P/E ratio of -28.79 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. Equities research analysts anticipate that CG Oncology will post -2.97 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Isabel Kalofonos acquired 3,751 shares of the firm’s stock in a transaction on Wednesday, November 18th. The shares were bought at an average cost of $79.75 per share, with a total value of $299,142.25. Following the completion of the acquisition, the insider owned 3,751 shares of the company’s stock, valued at $299,142.25. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Arthur Kuan acquired 30,000 shares of the stock in a transaction dated Wednesday, November 18th. The stock was bought at an average price of $78.88 per share, for a total transaction of $2,366,400.00. Following the completion of the purchase, the chief executive officer owned 228,916 shares in the company, valued at approximately $18,056,894.08. This trade represents a 15.08% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 3,000 shares of company stock valued at $227,040 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently modified their holdings of CGON. American Century Companies Inc. raised its stake in shares of CG Oncology by 0.6% in the third quarter. American Century Companies Inc. now owns 730,538 shares of the company’s stock valued at $51,788,000 after acquiring an additional 4,384 shares during the last quarter. Ghisallo Capital Management LLC acquired a new position in shares of CG Oncology in the 3rd quarter worth approximately $5,317,000. Virtu Financial LLC bought a new stake in CG Oncology during the 3rd quarter worth approximately $295,000. Aquatic Capital Management LLC grew its position in CG Oncology by 111.2% during the 3rd quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company’s stock worth $1,732,000 after acquiring an additional 12,867 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in CG Oncology by 32.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after acquiring an additional 278,751 shares during the last quarter. Institutional investors own 26.56% of the company’s stock.

Key Stories Impacting CG Oncology

Here are a few of the latest stories about CGON:

  • Positive Sentiment: Analysts raised targets and forecasts. Guggenheim lifted its price target to $120 from $89 and kept a Buy rating. HC Wainwright raised its longer-term earnings estimates and maintains a $115 target and Buy rating. Morgan Stanley also reportedly sees potential for strong appreciation. Guggenheim analyst coverage Morgan Stanley forecast
  • Positive Sentiment: Executives bought shares. CEO Arthur Kuan and another executive reportedly purchased about $2.7 million of CGON stock after the CEO described the company’s trial results as a “defining milestone.” A separate filing showed insider Isabel Kalofonos bought 3,751 shares for about $299,000. Such purchases may signal management confidence, though they do not guarantee future performance. Report on trial results and insider purchases
  • Neutral Sentiment: Clinical and financial uncertainty remains. CG Oncology is a clinical-stage biotech, and the cited earnings projections are several years out. Trial follow-up and regulatory progress remain important to the investment case.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Further Reading

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.